SynthesisESC heart failure2021
Heart failure and atrial flutter: a systematic review of current knowledge and practices.
Synthesis in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials.Heart failure reviews · 2023Pooled it
- Heart failure and atrial flutter: a systematic review of current knowledge and practices.ESC heart failure · 2021Pooled it
- When Palpitations Unmask Crista Terminalis Hypertrophy: A Case Report and Review of Current Literature.Diagnostics (Basel, Switzerland) · 2026Article
- Interplay of Atrial Arrhythmia and Chronic Heart Failure: A Population-Based Analysis of Hospital Outcomes in Germany.International journal of medical sciences · 2026Article
- A novel high dimensional approach to assess heterogeneous treatment effect in claims data.American journal of epidemiology · 2025Article
- Atrial fibrillation and flutter as global drivers of heart failure: Burden and longitudinal trends over three decades.ESC heart failure · 2025Article
- Optimal timing of electrical cardioversion for acute decompensated heart failure caused by atrial arrhythmias: The earlier, the better?Heart and vessels · 2024Article
- Association Between Family History and Early-Onset Atrial Flutter Across Racial and Ethnic Groups.Journal of the American Heart Association · 2024Article
- Cavotricuspid Isthmus-Dependent Atrial Flutter. Beyond Simple Linear Ablation.Reviews in cardiovascular medicine · 2024Review
- Clinical Characteristics of Atrial Flutter and Its Response to Pharmacological Cardioversion with Amiodarone in Comparison to Atrial Fibrillation.Journal of clinical medicine · 2023Article
- Impact of cavotricuspid isthmus ablation for typical atrial flutter and heart failure in the elderly-results of a retrospective multi-center study.Frontiers in cardiovascular medicine · 2023Article
- Polymyositis-Induced Atrial Flutter: A Rare and Unexpected Arrhythmia in an Idiopathic Inflammatory Myopathy.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While the interplay between heart failure (HF) and atrial fibrillation (AF) has been extensively studied, little is known regarding HF and atrial flutter (AFL), which may be managed differently. We reviewed the incidence, prevalence, and predictors of HF in AFL and vice versa, and the outcomes of treatment of AFL in HF. A systematic literature review of PubMed/Medline and EMBASE yielded 65 studies for inclusion and qualitative synthesis. No study described the incidence or prevalence of AFL in unselected patients with HF. Most cohorts enrolled patients with AF/AFL as interchangeable diagnoses, or highly selected patients with tachycardia-induced cardiomyopathy. The prevalence of HF in AFL ranged from 6% to 56%. However, the phenotype of HF was never defined by left ventricular ejection fraction (LVEF). No studies reported the predictors, phenotype, and prognostic implications of AFL in HF. There was significant variation in treatments studied, including the proportion that underwent ablation. When systolic dysfunction was tachycardia-mediated, catheter ablation demonstrated LVEF normalization in up to 88%, as well as reduced cardiovascular mortality. In summary, AFL and HF often coexist but are understudied, with no randomized trial data to inform care. Further research is warranted to define the epidemiology and establish optimal management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.